Skip to content
Companies

Holobiome

Gut bacteria probiotics aimed at depression

Raised to date

$10M

of $10M offered across 1 Form D filing

Investors
5
Last filed
Jul 22, 2026

About

Holobiome is a Boston-based microbiome platform biotechnology company founded in 2018 by research scientists from Northeastern University. It translates human gut microbiome science into next-generation probiotics and targeted therapeutics, with an initial focus on mapping and manipulating the gut-brain axis. The company maintains the Microbiome Vault, a growing strain collection aiming to be a comprehensive library of human gut bacteria, and its lead asset is a next-generation probiotic targeting biology relevant to depression. It has been backed by venture investors, NIH grants, and corporate partnerships including Unilever and Johnson & Johnson Consumer.

The Microbiome Vault strain bank plus deep expertise in cultivating previously unculturable gut bacteria lets Holobiome screen the microbiome for target activity, an approach that produced a lead gut-brain probiotic showing antidepressant-comparable effects in animal models.

Funding

  • OtherFiled Jul 22, 2026Form D
    $10M/ $10M

Product

Microbiome Vault platform

Biotechnology discovery platform

A microbiome discovery platform built on a continuously growing strain collection of human gut bacteria, international sample collection, and screening assays that make the microbiome searchable for target biological activity.

  • Comprehensive human gut bacteria strain bank
  • Expertise in cultivating hard-to-culture microbes
  • Screening for target activity across health areas

Built for

Consumer health and pharmaceutical partners commercializing probiotics and microbiome-based interventions, and ultimately patients with nervous-system and whole-body health conditions

People on file